Can-fite Biopharma CANF 深 沪
等待开盘 08-10 09:30:00 美东时间
3.4006
-0.099
-2.84%
华盛通- 最 高3.60
- 今 开3.33
- 成交量 2.87万股
- 最 低 3.19
- 昨 收 3.50
- 总市值 9.25万
- 52周最高 10.40
- 市盈率 静 --
- 换手率 105.60%
- 52周最低 0.1678
- 委 比 65.71%
- 总股本 2.72万
- 历史最高 141.90
- 量 比 0.67
- 振 幅 11.71%
- 历史最低 0.1678
- 每 手 1
- 风险率 1.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients
Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.
07-01 22:13
Market-Moving News for July 1st
NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom Energy shares are trading higher after the company announced it expanded its AI infrastructure partnership with
07-01 19:16
Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case
Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic disease opportunity.
06-26 22:08
Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseasesRamat Gan, Israel, June 26, 2026
06-26 19:04
Can-Fite Highlights Pancreatic Cancer Drug Progress
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today highlighted
06-02 19:02
Market-Moving News for March 4th
MRNA: 11% | Moderna shares are trading higher after the company announced that it has entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences. CANF: 54% | Can-Fite
03-04 20:20
Can-Fite Secures Brazilian Patent for Erectile Dysfunction Drug Candidate CF602
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today it received a
2025-11-20 20:04
Nasdaq Down 1%; Medtronic Earnings Top Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-11-19 01:53
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more th...
2025-11-18 22:55
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Can-Fite BioPharma's VP of Business Development, Dr. Sari Fishman, will present updates on the Phase IIa study of Namodenoson for advanced pancreatic cancer at the BIO 2025 Convention. The trial, led by Prof. Salomon Stemmer, has enrolled 50% of its target patients and shown a favorable safety profile.
2025-06-16 13:00
